Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability

Published August 6, 2026 · Category: Finance

Overview

Todd Watanabe, president and CEO of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) sold 4,375 shares on Aug. 3, 2026, according to a recent SEC Form 4 filing.

Transaction value based on SEC Form 4 weighted average sale price ($26.12); post-transaction value based on Aug. 3, 2026, market close ($25.94).

Arcutis Biotherapeutics is a specialized biopharmaceutical company with a market capitalization of $3.3 billion, operating with 354 employees and generating $415.62 million in TTM revenue. The company has established a focused pipeline of topical therapies for dermatological indications, with ARQ-151 representing its primary commercial asset.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

• My adult kids are big earners. Should I do a Roth conversion now so they aren’t taxed as much on their inheritance?
• Ford's new 'Fathom' electric pickup truck will start at $28,000
• Family offices back clean energy and sustainability startups in July as dealmaking holds steady